Abstract
The expression of disease is age related, occurring during or soon after periods of rapid somatic growth. Detectable cardiovascular abnormalities usually develop during adolescence.w5 For this reason the regular evaluation of the offspring of carriers during puberty and early adulthood is necessary for diagnosis and risk stratification. HCM has been described in infants and young children but data are limited. Children diagnosed before 14 years of age have a worse prognosis once they reach adolescence and early adulthood with a 2–4% annual incidence of sudden death.3 The development of clinical features of HCM in the elderly is associated with myosin binding protein C (MyBPC) mutations.w6 Although MyBPC disease appears benign in that presentation is in the later decades, once disease develops patients are at risk of all the recognised complications of HCM including arrhythmia, stroke, and sudden death.w7 A subanalysis of data from patients who had received an implantable cardioverter-defibrillator (ICD) indicated a higher proportion of individuals (40–50%) undergoing defibrillation in the age groups 11–20 years and > 55 years compared to the 21–55 years range.4 Aggressive management in these higher risk age groups may therefore be required.

This publication has 24 references indexed in Scilit: